West Pharmaceutical raises 2025 sales and EPS guidance after Q3 sales rise 7.7%
West Pharmaceutical Services reported third-quarter 2025 net sales of $804.6 million, up 7.7% from a year earlier, and diluted EPS of $1.92 versus $1.85. The company raised its full-year 2025 net sales guidance to $3.060 billion to $3.070 billion and adjusted-diluted EPS guidance to $7.06 to $7.11, and it introduced fourth-quarter guidance that is below the third-quarter level.
Key points
- Q3 net sales $804.6 million (up 7.7%, organic up 5.0%); HVP Components rose 16.3% to $390.0 million
- Q3 diluted EPS $1.92 vs. $1.85; adjusted-diluted EPS $1.96 vs. $1.85 a year earlier
- Full-year 2025 adjusted-diluted EPS guidance raised to $7.06 to $7.11, from $6.65 to $6.85
- Fourth-quarter 2025 net sales guidance of $790 million to $800 million and adjusted-diluted EPS guidance of $1.81 to $1.86
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.